Navigation Links
Spike in testicular cancer is focus

Pinpointing reasons behind the dramatic increase in testicular cancer, now the most common malignant cancer among 15-to-35-year-old Caucasian men, is the focus of a five-year, $5.5 million National Cancer Institute (NCI) grant to Yale Public Health researcher Tongzhang Zheng.

Testicular cancer is increasing for unknown reasons and this study will provide important information on possible environmental, genetic and other risk factors,?said Zheng, professor and head of the Division of Environmental Health Sciences in the Department of Epidemiology and Public Health at Yale School of Medicine.

Zheng will collaborate with researchers at Harvard School of Public Health and the Fred Hutchinson Cancer Research Center to conduct a population-based, case-control study on men in Connecticut and Massachusetts. The researchers will determine whether exposure to environmental factors such as environmental hormone disruptors increases the risk of testicular cancer. They will measure the levels of these environmental compounds in 800 patients with testicular cancer and in an equal number of unaffected control subjects.

Because so little is known about the potential environmental causes of testicular cancer, Zheng said, the team will collect and evaluate information on various major suspected risk factors, such as past medical history, history of hernia, venereal diseases, and any medication with androgens and other hormones. They will also examine lifetime occupational history, tobacco smoking, alcohol consumption and dietary information.

“Recent studies show that environmental exposures may affect development of testicular cancer,?said Zheng. “Determining risk factors that lead to testicular cancer, however is complicated because genetic susceptibility may modify a person’s risk from environmental exposures. We will try to assess the potential gene environment interaction on the manifestations of the disease.?


'"/>

Source:Yale University


Page: 1

Related biology news :

1. Study hints at role of stem cell genes in testicular, breast cancers
2. Viral DNA sequence a possible trigger for breast cancer
3. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
4. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
5. Columbia research lifts major hurdle to gene therapy for cancer
6. Combination therapy boosts effectiveness of telomere-directed cancer cell death
7. Mitochondrial DNA mutations play significant role in prostate cancer
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. BRCA1 causes ovarian cancer through indirect, biochemical route
10. Researchers identify target for cancer drugs
11. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... StarNet Communications ... solutions today announced the addition of a powerful “Session Preview” feature to its ... current state of the remote Linux desktop or other applications (sessions) they have ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
Breaking Biology Technology: